Victoria L Cressman1, Scott A Schobel1, Sara Steinfeld2, Shelly Ben-David2, Judy L Thompson1, Scott A Small3, Holly Moore4, Cheryl M Corcoran4. 1. Department of Psychiatry, Columbia University College of Physicians and Surgeons , New York, NY, USA. 2. The New York State Psychiatric Institute , New York, NY, USA. 3. Department of Neurology, Columbia University College of Physicians and Surgeons , New York, NY, USA. 4. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA; The New York State Psychiatric Institute, New York, NY, USA.
Abstract
BACKGROUND/ OBJECTIVES: Anhedonia is associated with poor social function in schizophrenia. Here, we examined this association in individuals at clinical high risk (CHR) for schizophrenia and related psychotic disorders, taking into account social anxiety. We then explored correlations between anhedonia and basal metabolic activity in selected forebrain regions implicated in reward processing. METHODS: In 62 CHR individuals and 37 healthy controls, we measured social adjustment (Social Adjustment Self-Report Scale), social and physical anhedonia (Chapman Revised Anhedonia Scales), and social anxiety (Social Anxiety Scale for Adolescents) in cross-section. In a subgroup of 25 CHR individuals for whom high-spatial-resolution basal-state functional magnetic resonance imaging data were available, we also assessed correlations of these socio-affective constructs with basal cerebral blood volume in orbitofrontal cortex and related regions involved in reward processing. RESULTS: Relative to controls, CHR individuals reported social impairment, greater social and physical anhedonia, and more social anxiety, exhibiting impairments comparable to schizophrenia. Regression analyses showed that anhedonia predicted social impairment and correlated negatively with basal cerebral blood volume within the orbitofrontal cortex (all P's<0.05). CONCLUSIONS: Anhedonia and social anxiety are prominent in CHR individuals. Trait-like anhedonia may be a core phenotype related to orbitofrontal cortical function that, independent of symptoms, predicts social impairment. These data provide a rationale for interventions that target anhedonia and related activity in orbitofrontal cortical circuits in CHR individuals.
BACKGROUND/ OBJECTIVES: Anhedonia is associated with poor social function in schizophrenia. Here, we examined this association in individuals at clinical high risk (CHR) for schizophrenia and related psychotic disorders, taking into account social anxiety. We then explored correlations between anhedonia and basal metabolic activity in selected forebrain regions implicated in reward processing. METHODS: In 62 CHR individuals and 37 healthy controls, we measured social adjustment (Social Adjustment Self-Report Scale), social and physical anhedonia (Chapman Revised Anhedonia Scales), and social anxiety (Social Anxiety Scale for Adolescents) in cross-section. In a subgroup of 25 CHR individuals for whom high-spatial-resolution basal-state functional magnetic resonance imaging data were available, we also assessed correlations of these socio-affective constructs with basal cerebral blood volume in orbitofrontal cortex and related regions involved in reward processing. RESULTS: Relative to controls, CHR individuals reported social impairment, greater social and physical anhedonia, and more social anxiety, exhibiting impairments comparable to schizophrenia. Regression analyses showed that anhedonia predicted social impairment and correlated negatively with basal cerebral blood volume within the orbitofrontal cortex (all P's<0.05). CONCLUSIONS:Anhedonia and social anxiety are prominent in CHR individuals. Trait-like anhedonia may be a core phenotype related to orbitofrontal cortical function that, independent of symptoms, predicts social impairment. These data provide a rationale for interventions that target anhedonia and related activity in orbitofrontal cortical circuits in CHR individuals.
Authors: K A Hawkins; T H McGlashan; D Quinlan; T J Miller; D O Perkins; R B Zipursky; J Addington; S W Woods Journal: Schizophr Res Date: 2004-06-01 Impact factor: 4.939
Authors: James M Gold; Gregory P Strauss; James A Waltz; Benjamin M Robinson; Jamie K Brown; Michael J Frank Journal: Biol Psychiatry Date: 2013-02-07 Impact factor: 13.382
Authors: Jimmy Choi; Cheryl M Corcoran; Joanna M Fiszdon; Michael Stevens; Daniel C Javitt; Melissa Deasy; Lawrence C Haber; Michael J Dewberry; Godfrey D Pearlson Journal: Psychiatr Rehabil J Date: 2016-08-25
Authors: Andrea Pelletier-Baldelli; Gregory P Strauss; Franchesca S Kuhney; Charlotte Chun; Tina Gupta; Lauren M Ellman; Jason Schiffman; Vijay A Mittal Journal: J Psychiatr Res Date: 2021-01-11 Impact factor: 4.791
Authors: Valerie J Sydnor; Bart Larsen; Christian Kohler; Andrew J D Crow; Sage L Rush; Monica E Calkins; Ruben C Gur; Raquel E Gur; Kosha Ruparel; Joseph W Kable; Jami F Young; Sanjeev Chawla; Mark A Elliott; Russell T Shinohara; Ravi Prakash Reddy Nanga; Ravinder Reddy; Daniel H Wolf; Theodore D Satterthwaite; David R Roalf Journal: Mol Psychiatry Date: 2021-01-21 Impact factor: 13.437
Authors: LeeAnn Akouri-Shan; Jason Schiffman; Zachary B Millman; Caroline Demro; John Fitzgerald; Pamela J Rakhshan Rouhakhtar; Samantha Redman; Gloria M Reeves; Shuo Chen; James M Gold; Elizabeth A Martin; Cheryl Corcoran; Jonathan P Roiser; Robert W Buchanan; Laura M Rowland; James A Waltz Journal: Schizophr Bull Date: 2021-10-21 Impact factor: 7.348
Authors: Francesco Amico; Erik O'Hanlon; Dominik Kraft; Viola Oertel-Knöchel; Mary Clarke; Ian Kelleher; Niamh Higgins; Helen Coughlan; Daniel Creegan; Mark Heneghan; Emmet Power; Lucy Power; Jessica Ryan; Thomas Frodl; Mary Cannon Journal: PLoS One Date: 2017-01-26 Impact factor: 3.240